Oxidopamine
Research News and Information

Saturday, November 21, 2009

Reward-seeking and discrimination deficits displayed by hypodopaminergic mice are prevented in mice lacking dopamine D4 receptors.

30 Oct 2009 The dopamine D4 receptor (D4R) is predominantly expressed in the prefrontal cortex, a brain area that integrates motor, rewarding, and cognitive information. Because participation of D4Rs in executive learning is largely unknown, we challenged D4R ... Read more...

CIB1 functions as a Ca(2+)-sensitive modulator of stress-induced signaling by targeting ASK1.

27 Sep 2009 Calcium and integrin binding protein 1 (CIB1) is a Ca(2+)-binding protein of 22 kDa that was initially identified as a protein that interacts with integrin alpha(IIb). Although it interacts with various proteins and has been implicated in diverse ... Read more...

Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.

21 Sep 2009 Dopamine replacement therapy for the treatment of Parkinson's disease leads to deleterious abnormal involuntary movements (AIMs), known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia, which parallels enhanced striatal dopamine D1 ... Read more...

Latest indexed articles for 'Oxidopamine'

These are the very latest articles for this heading:

• Reward-seeking and discrimination deficits displayed by hypodopaminergic mice are prevented in mice lacking dopamine D4 receptors. 30 Oct 2009
• CIB1 functions as a Ca(2+)-sensitive modulator of stress-induced signaling by targeting ASK1. 27 Sep 2009
• Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. 21 Sep 2009
• Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. 30 Aug 2009
• Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats. 25 Aug 2009
• Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism. 20 Aug 2009
• Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats. 15 Aug 2009
• Organotypic cultures as a model of Parkinson s disease. A twist to an old model. 9 Aug 2009
• Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. 8 Aug 2009
• Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling. Aug 2009
• Persistent short-term memory defects following sleep deprivation in a drosophila model of Parkinson disease. 30 Jul 2009
• NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease. 30 Jul 2009
• The role of the neural sympathetic and parasympathetic systems in diurnal and sleep state-related cardiovascular rhythms in the late-gestation ovine fetus. 27 Jul 2009
• Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. 27 Jul 2009
• Marked behavioral activation from inhibitory stimulation of locus coeruleus alpha1-adrenoceptors by a full agonist. 22 Jul 2009
• The electrocorticogram signal can be modulated with deep brain stimulation of the subthalamic nucleus in the hemiparkinsonian rat. 20 Jul 2009
• Neural cell protective compounds isolated from Phoenix hanceana var. formosana. 19 Jul 2009
• Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. 16 Jul 2009
• Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. 13 Jul 2009
• Grafted neural stem cells migrate to substantia nigra and improve behavior in Parkinsonian rats. 7 Jul 2009

See a longer list of these articles.

Technical information about 'Oxidopamine'

Definition: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.

Chemical name: 1,2,4-Benzenetriol, 5-(2-aminoethyl)-

Registry Number: 1199-18-4

Descriptor UI: D016627

Alternative terms: Oxidopamine; 6-OHDA; 6-Hydroxydopamine; 6 Hydroxydopamine; Oxidopamine Hydrochloride; Hydrochloride, Oxidopamine; Oxidopamine Hydrobromide; Hydrobromide, Oxidopamine;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Sympatholytics; Adrenergic Agents;

Tree Number: D02.092.311.342.478.650;

Online Note: use OXIDOPAMINE (NM) to search 6-HYDROXYDOPAMINE (NM) 1980-91

History Note: 92; was 6-HYDROXYDOPAMINE (NM) 1981-91